Screener
Mineralys Therapeutics, Inc. MLYS Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets.
The source filing: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 5:19 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001933414-26-000056
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Net operating loss carryforwards | $55,102 | $15,580 |
| Research and development credit carryforwards | 21,169 | 15,380 |
| Capitalized research and development costs | 39,935 | 44,981 |
| Intangible assets | 1,823 | 1,976 |
| Other | 3,219 | 2,012 |
| Total deferred tax assets | 121,248 | 79,929 |
| Valuation allowance | (121,248) | (79,929) |
| Deferred tax assets, net of valuation allowance | — | — |
Item 8. F-1 Item 8. Financial Statements and Supplementary Data
FAQ
- What is Mineralys Therapeutics, Inc.'s intangibles (net)?
- Mineralys Therapeutics, Inc. (MLYS) reported intangibles (net) of $1.82M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s intangibles (net)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s intangibles (net) has grown at a 89.0% compound annual growth rate (CAGR), from $270K to $1.82M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Mineralys Therapeutics, Inc.'s intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude